PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 8, 2026Drug Metabolism Reviews0 citations

Exploring the clinical pharmacokinetics and pharmacodynamics of SGLT2 inhibitor, empagliflozin: a systematic review

View Full Paper
TSTahir SaleemMRMuhammad Fawad RasoolHSHamid Saeed

Key Points

  • The review aims to consolidate pharmacokinetic and pharmacodynamic data for empagliflozin to guide clinical use in specific populations.
  • Systematic review of available studies on empagliflozin's pharmacokinetics (PK) and pharmacodynamics (PD).
  • Analysis focused on patients with renal and hepatic impairment and type 2 diabetes.
  • Evaluation aimed at determining optimal dosing and minimizing adverse drug interactions.
  • Empagliflozin PK parameters showed a 1.1-fold increase when given alone, but reduced in combination with linagliptin.
  • Findings assist in clinical decision-making regarding dose adjustments in special populations.
  • Highlights the importance of monitoring for adverse reactions and drug interactions in patients.

Abstract

that was 1.1-fold greater when administered alone but decreased in the presence of linagliptin. This systematic review consolidates all available PK and PD parameters of empagliflozin from accessible studies to assist clinicians in dose adjustment for patients with renal or hepatic impairment and type 2 diabetes, as well as in minimizing the risk of adverse reactions and drug-drug interactions.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Saleem et al. (2026) studied this question.

synapsesocial.com/papers/69fd7ef7bfa21ec5bbf07517https://doi.org/10.1080/03602532.2026.2668704
Ask AI
Helpful
Bookmark
Share
View Full Paper